2024
Unmet needs in cervical cancer – can biological therapies plug the gap?
Greenman M, Chang Y, McNamara B, Mutlu L, Santin A. Unmet needs in cervical cancer – can biological therapies plug the gap? Expert Opinion On Biological Therapy 2024, 24: 995-1003. PMID: 39311611, DOI: 10.1080/14712598.2024.2408754.Peer-Reviewed Original ResearchBiologic therapyCervical cancerIntroduction of biologic therapiesManagement of cervical cancerImmune checkpoint inhibitorsIncreased overall survivalCurrent treatment recommendationsMultiple tumor typesAntibody-drug conjugatesCheckpoint inhibitorsOverall survivalRecurrent diseaseGynecologic malignanciesTreat malignanciesTumor typesClinical outcomesAngiogenesis inhibitorsBurden of casesTreatment recommendationsTherapyImprove current standardsAntitumor activityInadequate screeningCancerMalignancy
2021
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis
McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, Leung S, Bellone S, Wong A, Brucker SY, Lee CH, Clarke BA, Huntsman DG, Bernardini MQ, Ngeow J, Santin AD, Goodfellow P, Levine DA, Köbel M, Kommoss S, Bosse T, Gilks CB, Talhouk A. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis. Cancer 2021, 127: 2409-2422. PMID: 33793971, DOI: 10.1002/cncr.33516.Peer-Reviewed Original ResearchConceptsIndividual patient dataEndometrial cancerPOLE mutationsAdjuvant treatmentAdverse eventsSalvage rateClinical outcomesMeta-analyses (PRISMA) reporting guidelinesConcerns of overtreatmentPathogenic POLE mutationsPatient dataEvidence of diseaseRecurrence/progressionTraditional prognostic factorsProgression/recurrenceUnfavorable pathological featuresAssociation of treatmentMixed effects Cox modelPreferred Reporting ItemsAdditional therapyAdjuvant therapyLess therapyPrognostic factorsFirst diagnosisPathological features
2019
GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study
Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology 2019, 153: 335-342. PMID: 30827726, PMCID: PMC6486855, DOI: 10.1016/j.ygyno.2019.02.028.Peer-Reviewed Original ResearchConceptsProgression-free survivalLymph node metastasisHazard ratioOverall survivalNode metastasisSingle nucleotide polymorphismsOdds ratioNRG Oncology/Gynecologic Oncology Group studyG alleleGynecologic Oncology Group studyEndometrioid endometrial cancer patientsGynecologic Oncology GroupEndometrial cancer patientsPrognostic clinical variablesWorse OSOncology GroupEEC patientsEndometrial cancerNodal metastasisPrimary outcomeClinical outcomesRisk stratificationWashington University SchoolClinical variablesCancer patients
2015
Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review
Roque DM, Ratner ES, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Nelson WK, Santin AD. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. Gynecologic Oncology 2015, 137: 392-400. PMID: 25792179, DOI: 10.1016/j.ygyno.2015.03.008.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDisease-Free SurvivalDrug Administration ScheduleEpothilonesFallopian Tube NeoplasmsFemaleHumansMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPeritoneal NeoplasmsProspective StudiesRetrospective StudiesConceptsObjective response rateFallopian tube cancerWeekly ixabepiloneOvarian cancerConcurrent bevacizumabRetrospective reviewMedian PFS/OSSimilar objective response ratesWarrants further prospective studySingle-institution retrospective reviewCA-125 criteriaPFS/OSTreatment of recurrentKaplan-Meier methodFurther prospective studiesBiweekly bevacizumabMedian PFSAcceptable toxicityGrade 1/2Median durationOverall survivalPrior linesClinical outcomesProspective studyUterine cancer
2013
Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel
Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clinical & Experimental Metastasis 2013, 31: 101-110. PMID: 24005572, PMCID: PMC3947146, DOI: 10.1007/s10585-013-9614-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarboplatinCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleHumansImmunohistochemistryNeoadjuvant TherapyOvarian NeoplasmsPaclitaxelPrognosisReal-Time Polymerase Chain ReactionTubulinTumor MicroenvironmentUp-RegulationConceptsClass III β-tubulinIII β-tubulinClass III β-tubulin expressionNeoadjuvant chemotherapyPoor overall survivalOverall survivalΒ-tubulin expressionClass III β-tubulin overexpressionPrimary cytoreductionNeoadjuvant carboplatin/paclitaxelPoor median overall survivalTumor microenvironmentAdvanced ovarian carcinomaCarboplatin/paclitaxelMedian overall survivalOvarian cancer patientsCell linesCancer stem cellsNeoadjuvant carboplatinPrimary debulkingVitro chemosensitivityClinical outcomesPatient populationCancer patientsStromal expressionTubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones
Roque DM, Bellone S, English DP, Buza N, Cocco E, Gasparrini S, Bortolomai I, Ratner E, Silasi D, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 2013, 119: 2582-2592. PMID: 23585021, PMCID: PMC3700638, DOI: 10.1002/cncr.28017.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCystadenocarcinoma, SerousDrug Resistance, NeoplasmEpothilonesFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMiddle AgedNeoplasm StagingPaclitaxelPlatinum CompoundsPredictive Value of TestsPrognosisReal-Time Polymerase Chain ReactionTubulinTubulin ModulatorsUp-RegulationUterine NeoplasmsConceptsUterine serous carcinomaOvarian serous carcinomaOverall survivalSerous carcinomaP-glycoproteinClinical outcomesPaclitaxel resistanceTreatment of USCPlatinum/taxane chemotherapyPoor overall survivalFresh frozen tissue samplesReal-time polymerase chain reactionCell linesTaxane chemotherapyEndometrial cancerPoor outcomePoor prognosisPolymerase chain reactionFresh frozen tissueMedian inhibitory concentrationClinical investigationSubset of individualsGlycoprotein expressionCarcinomaImmunohistochemistryClass III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone
Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. American Journal Of Obstetrics And Gynecology 2013, 209: 62.e1-62.e9. PMID: 23583215, DOI: 10.1016/j.ajog.2013.04.017.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Cell LineCystadenocarcinoma, SerousDose-Response Relationship, DrugDown-RegulationDrug Resistance, NeoplasmEpothilonesFemaleHumansImmunohistochemistryKaplan-Meier EstimateMicrotubulesNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPrognosisReal-Time Polymerase Chain ReactionTaxoidsTubulinTubulin ModulatorsConceptsClass III β-tubulinClear cell carcinomaIII β-tubulinCell carcinomaOverall survivalP-glycoproteinClass III β-tubulin overexpressionClinical outcomesPolymerase chain reactionPaclitaxel resistanceClass III β-tubulin expressionPlatinum/taxane chemotherapyPoor overall survivalSerous papillary carcinomaChain reactionOvarian clear cellFresh frozen tissue samplesReal-time polymerase chain reactionCell linesTime polymerase chain reactionPolymerase chain reaction resultsΒ-tubulin expressionTaxane chemotherapyPoor outcomePoor prognosis
2009
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence
Tassi RA, Calza S, Ravaggi A, Bignotti E, Odicino FE, Tognon G, Donzelli C, Falchetti M, Rossi E, Todeschini P, Romani C, Bandiera E, Zanotti L, Pecorelli S, Santin AD. Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. BMC Cancer 2009, 9: 253. PMID: 19635143, PMCID: PMC2724548, DOI: 10.1186/1471-2407-9-253.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancerEOC patientsMammaglobin BFresh-frozen tissue biopsiesMultiple histological subtypesDisease-free survivalLong-term prognosisAdditional prognostic informationRisk of recurrenceIndependent prognostic markerIndependent prognostic valueProtein levelsUnivariate survival analysisCancer-related deathAggressive tumor behaviorNormal ovarian controlsPrimary surgeryClinicopathologic characteristicsDisease recurrencePrognostic factorsClinical outcomesClinicopathologic featuresDecreased riskHistological subtypes
2003
Influence of Allogeneic Blood Transfusion on Clinical Outcome during Radiotherapy for Cancer of the Uterine Cervix
Santin AD, Bellone S, Parrish RS, Coke C, Dunn D, Roman J, Theus JW, Cannon MJ, Parham GP, Pecorelli S. Influence of Allogeneic Blood Transfusion on Clinical Outcome during Radiotherapy for Cancer of the Uterine Cervix. Gynecologic And Obstetric Investigation 2003, 56: 28-34. PMID: 12867765, DOI: 10.1159/000072328.Peer-Reviewed Original ResearchConceptsAllogeneic blood transfusionStage IIB patientsStage III patientsBlood transfusionRadiation treatmentCervical cancerRisk ratioIndependent variable predictivePrimary radiation treatmentRoutine blood transfusionProspective Randomized StudyCervical cancer patientsOnset of treatmentDuration of treatmentTotal radiation doseUntransfused groupException of hemoglobinRandomized studyClinical outcomesUterine cervixImmune suppressionCervical carcinomaCancer patientsDistribution of ageDiminished survival